Your browser doesn't support javascript.
Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis.
Donlan, Alexandra N; Mallawaarachi, Indika; Sasson, Jennifer M; Preissner, Robert; Loomba, Johanna J; Petri, William A.
  • Donlan AN; Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Mallawaarachi I; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Sasson JM; Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Preissner R; Science-IT and Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Loomba JJ; Integrated Translational Health Research Institute (iTHRIV).
  • Petri WA; Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Clin Infect Dis ; 2022 Sep 15.
Article in English | MEDLINE | ID: covidwho-2229562
ABSTRACT
We previously found that type 2 immunity promotes COVID-19 pathogenesis in a mouse model. To test relevance to human disease we used electronic health record databases and determined that patients on dupilumab (anti-IL-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid